Primary study end point of exacerbation rate and time to a normal platelet count
| . | Prednisone/PEX*† (n=14) . | CSA/PEX* (n=12) . |
|---|---|---|
| Time to normal platelet count, median days (range) | 5 (4-8) | 5 (4-19) |
| Response rate, n/n (%) | 11/14 (79) | 11/12 (92) |
| Exacerbation rate, n/n (%) | 1/11 (9) | 3/11 (27) |
| . | Prednisone/PEX*† (n=14) . | CSA/PEX* (n=12) . |
|---|---|---|
| Time to normal platelet count, median days (range) | 5 (4-8) | 5 (4-19) |
| Response rate, n/n (%) | 11/14 (79) | 11/12 (92) |
| Exacerbation rate, n/n (%) | 1/11 (9) | 3/11 (27) |
There was no significant difference between the exacerbation rates in the prednisone arm vs the CSA arm (P = 0.3).
*There was 1 death in each arm of the study.
†Two patients who were refractory to prednisone crossed over to the CSA arm.